South Carolina's only NCI-designated cancer centre, known for tobacco control, colorectal cancer prevention science and lipid signalling research.
NCI-designated since 2009, Hollings Cancer Center at the Medical University of South Carolina is the state's only NCI centre and covers a catchment with pronounced rural and racial disparities. Director Raymond DuBois's work on COX-2 and prostaglandins in colorectal cancer established a basis for aspirin and NSAID chemoprevention, and the centre's sphingolipid signalling programme (built by Yusuf Hannun and Lina Obeid) is internationally known. Hollings runs statewide tobacco cessation and lung screening programmes, a strong head and neck cancer service, and proton therapy through MUSC Health. It participates in NCI cooperative group trials and runs an early-phase unit.
From OpenAlex, oncology works in the last five years (2022 to 2026, current year in progress); counted on 2026-09-16.
Matched to MUSC Hollings Cancer Center, including child institutions. 178 works · 1,608 citations · 74% open access · 22% clinical trials · 2% reviews.
Shares NCI-Designated Cancer Centers, Chemoprevention & risk-reducing surgery, Prevention we already have is not deployed, National Cancer Institute (NIH).
Shares Low-dose CT lung screening, Prevention we already have is not deployed, National Cancer Institute (NIH), Colorectal cancer.
Shares NCI-Designated Cancer Centers, Proton therapy, National Cancer Institute (NIH), Head and neck squamous cell carcinoma.
Shares NCI-Designated Cancer Centers, Proton therapy, National Cancer Institute (NIH), Colorectal cancer.
Shares NCI-Designated Cancer Centers, National Cancer Institute (NIH), Non-small-cell lung cancer.
Shares NCI-Designated Cancer Centers, National Cancer Institute (NIH), Non-small-cell lung cancer.
Shares NCI-Designated Cancer Centers, Proton therapy, National Cancer Institute (NIH).
Shares NCI-Designated Cancer Centers, Proton therapy, National Cancer Institute (NIH).